Bjerrum JT, et al. - This examination utilizes spectroscopy-based metabolic profiling of serum from patients with inflammatory bowel disease (IBD) treated with infliximab (IFX) and healthy subjects (1) to substantiate the utilization of spectroscopy as a semi-invasive diagnostic tool, (2) to recognize potential biomarkers of treatment response and (3) to describe the metabolic changes amid management of patients with tumour necrosis factor-α inhibitors. This study revealed that the ¹H NMR spectroscopy of serum samples is a powerful semi-invasive diagnostic tool in flaring IBD. With its utilization, they provide unique insights into the metabolic changes taking place amid induction treatment with IFX. Of distinct clinical relevance is the identification of a reversible proatherogenic lipid profile in IBD patients with active disease, which partially clarifies the increased risk of cardiovascular disease related to IBD.